Clinical Trials
78
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (72 trials with phase data)• Click on a phase to view related trials
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
- Conditions
- Nonalcoholic Steatohepatitis (NASH)Non-alcoholic Fatty Liver Disease (NAFLD)Metabolic Dysfunction-Associated Steatohepatitis (MASH)Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Interventions
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-08-14
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 8
- Registration Number
- NCT06947304
- Locations
- 🇺🇸
University of Missouri, Columbia, Missouri, United States
Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 19
- Registration Number
- NCT06928779
- Locations
- 🇺🇸
Site 2, Rialto, California, United States
🇺🇸Site 1, Miami, Florida, United States
Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
- Conditions
- Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms
- Interventions
- First Posted Date
- 2025-04-02
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 90
- Registration Number
- NCT06906341
- Locations
- 🇺🇸
544, Fort Myers, Florida, United States
🇺🇸543, West Palm Beach, Florida, United States
🇺🇸334, Kansas City, Missouri, United States
Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)
- Conditions
- Resistant HypertensionHypercortisolism
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-10-10
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 1000
- Registration Number
- NCT06829537
- Locations
- 🇺🇸
Site 041, Los Angeles, California, United States
🇺🇸Site 554, Miami, Florida, United States
🇺🇸Site 552, Chicago, Illinois, United States
Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 21
- Registration Number
- NCT06495944
- Locations
- 🇺🇸
Site 01, Baltimore, Maryland, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 14
- Next
News
FDA Approves Osilodrostat for Second-Line Cushing Syndrome Treatment as Pipeline Advances
The FDA approved osilodrostat (Isturisa) as a second-line treatment for adults with endogenous Cushing syndrome in April 2025, expanding treatment options for patients unable to undergo surgery.
MBX Biosciences Strengthens Leadership with Endocrinology Expert to Advance Hypoparathyroidism Treatment
MBX Biosciences appointed Andreas Moraitis, M.D., as Senior Vice President of Clinical Development to lead advancement of canvuparatide for hypoparathyroidism treatment.
Oncology Clinical Trials Embrace AI and Digital Solutions to Enhance Patient-Centric Approaches
Industry experts at the 15th Annual Clinical Trial in Oncology West Coast conference highlighted AI's transformative potential in matching the right patient populations with appropriate therapies to improve trial success rates.
Study Reveals 24% of Difficult-to-Control Type 2 Diabetes Patients Have Hypercortisolism
Corcept Therapeutics' CATALYST trial, the largest study of its kind, found that nearly one-quarter of patients with difficult-to-control type 2 diabetes have hypercortisolism, a condition caused by excessive cortisol activity.
Corcept Therapeutics Submits New Drug Application for Relacorilant to Treat Cushing's Syndrome
Corcept Therapeutics has submitted a New Drug Application to the FDA for relacorilant, a selective cortisol modulator designed to treat patients with endogenous hypercortisolism (Cushing's syndrome).
Relacorilant Shows Durable Cardiometabolic Benefits in Cushing's Syndrome Patients
Corcept Therapeutics' relacorilant demonstrates sustained improvements in cardiometabolic measures in patients with Cushing's syndrome over six years.
Mifepristone Demonstrates Significant HbA1c Reduction in CATALYST Trial for Hypercortisolism and Difficult-to-Control Type 2 Diabetes
Mifepristone (Korlym) achieved a statistically significant 1.32% placebo-adjusted reduction in HbA1c in patients with hypercortisolism and difficult-to-control type 2 diabetes.
Dazucorilant Fails Primary Endpoint in Phase 2 ALS Trial but Shows Survival Benefit
Corcept Therapeutics' dazucorilant did not meet the primary endpoint in the DAZALS Phase 2 trial for amyotrophic lateral sclerosis (ALS).
Relacorilant Plus Nab-Paclitaxel Shows Promise in Platinum-Resistant Ovarian Cancer
Relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel, demonstrates potential in treating platinum-resistant ovarian cancer.
Relacorilant Fails to Meet Primary Endpoint in GRADIENT Trial for Cushing's Syndrome
Corcept Therapeutics' Phase III GRADIENT trial of relacorilant in Cushing's syndrome did not meet its primary endpoint of statistically significant improvement in systolic blood pressure.